HK Stock MarketDetailed Quotes

01167 JACOBIO-B

Watchlist
  • 1.620
  • -0.010-0.61%
Market Closed Mar 28 16:08 CST
1.28BMarket Cap-3233P/E (TTM)

About JACOBIO-B Company

Garcos Pharmaceutical Group Co., Ltd. is committed to providing patients with breakthrough treatment solutions. The company's vision is to work hand in hand with partners to become a globally recognized leader in drug development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platforms have the technology to develop modified inhibitors of protein phosphatase, KRAS, and other transcription factors. Gacos has received investments from several biotechnology-specialized investment institutions, including Qiming Ventures, Lilly Asia Fund, Gao Lin, and Taiwan's Yu Sheng.

Company Profile

Symbol01167
Company NameJACOBIO-B
ISINKYG4987A1094
Listing Date12/21/2020
Issue Price14.00
Shares Offered96.48M share
Founded06/01/2018
RegistrationCayman Islands
ChairmanYinxiang Wang
SecretaryQing\zhongminghui Xue
Audit InstitutionPricewaterhouseCoopers
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeWalkers Corporate Limited, 190 Elgin Avenue, George Town,Grand Cayman KY1-9008, Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees301
MarketHong Kong motherboard
Phone(010)56315466
Fax(010)56315314
EmailIR@jacobiopharma.com
Business Garcos Pharmaceutical Group Co., Ltd. is a Chinese investment holding company mainly engaged in the development of new clinical-stage drugs. The company is mainly responsible for the independent discovery and development of innovative oncology treatments. The company's major drug development projects include JAB-3068 and JAB-3312 clinical-stage modified SHP2 inhibitors. The company mainly operates in the domestic market.

Company Executives

  • Name
  • Position
  • Salary
  • Yinxiang Wang
  • CEO,Executive Director,Chairman,Nomination Committee Chairman
  • 3.77M
  • Xiaojie Wang
  • CEO,Authorized Representative,Executive Director,Remuneration Committee Member
  • 2.86M
  • Yunyan Hu
  • Executive Director,Senior VP
  • 2.84M
  • Yanmin Tang
  • Nomination Committee Member,Remuneration Committee Member,Non-Executive Director
  • --
  • Deli Chen
  • Audit Committee Member,Non-Executive Director
  • --
  • Ruilin Song
  • Nomination Committee Member,Independent Non-Executive Director,Remuneration Committee Chairman
  • 400.00K
  • Ge Wu
  • Nomination Committee Member,Audit Committee Member,Remuneration Committee Member,Independent Non-Executive Director
  • 200.00K
  • Bai Lu
  • Audit Committee Chairman,Remuneration Committee Member,Nomination Committee Member,Independent Non-Executive Director
  • --
  • Yi Wang
  • Senior VP,Chief Medical Officer
  • --
  • Qing Xue
  • Joint Company Secretary
  • --
  • Minghui Zhong
  • Authorized Representative,Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg